Iceland· IS-EU/1/17/1234/002-003
Tremfya
A guselkumab product containing guselkumabum inn, registered in Iceland by Janssen-Cilag International NV*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Guselkumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC16 (guselkumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Guselkumab · ATC L04AC16
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of guselkumab costs, country by country.
Normalised to the WHO defined daily dose (1.79 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Guselkumab · price per daily dose (1.79 mg)
USD · FX 28 Sept 2026
- CH Switzerland$44.94
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Guselkumabum INN
- Manufacturer
- Janssen-Cilag International NV*
- Country
- Iceland (IS)
- ATC code
- L04AC16
- ATC class
- Guselkumab
- Defined daily dose
- 1.79 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
149 interactions on record for guselkumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Guselkumab · interactions on record
149 records
- 27 severe
- 115 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Guselkumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTREMFYAJanssen-Cilag International N.V., Beerse
- SwitzerlandTremfya 100 mg/1 ml, Injektionslösung im FertigpenJanssen-Cilag AG
- SwedenTremfya (OnePress) 100 mg Injektionsvätska, lösning i förfylld injektionspennaJanssen-Cilag International NV
- NetherlandsTremfya 100 mg OnePress oplossing voor injectie in een voorgevulde penJanssen-Cilag International NV
- BelgiumTremfya 100 mgJanssen-Cilag International
- FinlandTremfyaJanssen Cilag International
- United StatesTREMFYAJanssen Biotech, Inc.
- SpainTREMFYA 100 MG ONEPRESS SOLUCION INYECTABLE EN PLUMA PRECARGADAJanssen-Cilag International N.V
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Tremfya
- Norway · Tremfya
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f00473d2-6a12-46f3-ba2e-11e130897fe1 GET /v1/drugs/f00473d2-6a12-46f3-ba2e-11e130897fe1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn í áfylltum lyfjapenna",
"source": "lyfjastofnun",
"atc_raw": "L04AC16",
"marketed": true,
"strength": null,
"ma_number": "EU/1/17/1234/002-003",
"substance": "Guselkumabum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í gigtarlækningum, húðsjúkdómum, meltingarsjúkdómum og ónæmisfræði.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "43293"
}See everything about guselkumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.